Top Page
Jaguar Animal Health
(NASDAQ:JAGX)
Jaguar Animal Health (JAGX) vs. SPDR S&P 500 ETF (SPY)
Jaguar Animal Health Business Overview & Revenue Model
Jaguar Animal Health Earnings Call Summary
Jaguar Animal Health Financial Statement Overview
| Breakdown | |||||
| TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|
| Income Statement | Total Revenue | ||||
| 11.51M | 11.69M | 9.76M | 11.96M | 4.33M | 9.38M | Gross Profit |
| 9.47M | 9.73M | 7.72M | 9.94M | 2.00M | 6.11M | EBIT |
| -32.04M | -30.83M | -34.29M | -34.41M | -39.07M | -21.30M | EBITDA |
| -38.48M | -36.66M | -33.13M | -33.38M | -42.35M | -28.74M | Net Income Common Stockholders |
| -39.73M | -38.49M | -41.30M | -47.45M | -60.25M | -36.79M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
| 5.69M | 8.00M | 6.47M | 5.47M | 17.05M | 8.09M | Total Assets |
| 51.46M | 53.42M | 50.76M | 47.45M | 53.27M | 42.84M | Total Debt |
| 38.34M | 36.53M | 37.09M | 34.84M | 29.36M | 16.21M | Net Debt |
| 32.65M | 28.52M | 30.63M | 29.37M | 12.31M | 8.12M | Total Liabilities |
| 48.15M | 46.93M | 45.87M | 48.81M | 41.41M | 25.64M | Stockholders Equity |
| 830.00K | 7.29M | 4.96M | -657.00K | 11.61M | 17.20M |
| Cash Flow | Free Cash Flow | ||||
| -29.87M | -29.61M | -33.24M | -34.78M | -34.98M | -15.29M | Operating Cash Flow |
| -29.65M | -29.38M | -33.24M | -33.10M | -34.97M | -15.28M | Investing Cash Flow |
| -231.00K | -231.00K | 1.23M | -1.68M | -6.00K | -7.00K | Financing Cash Flow |
| 23.90M | 31.20M | 34.23M | 23.18M | 43.94M | 19.49M |
Jaguar Animal Health Technical Analysis
Jaguar Animal Health Risk Analysis
Jaguar Animal Health Peers Comparison
Jaguar Animal Health Corporate Events
On May 20, 2025, Jaguar Health, Inc. entered into a securities purchase agreement for a registered direct offering of 246,306 shares of common stock at $6.09 per share, expected to raise approximately $1.5 million. The offering, set to close around May 22, 2025, includes a concurrent private placement of unregistered warrants to purchase up to 492,612 shares. The proceeds will be used for corporate purposes, including working capital and debt repayment. H.C. Wainwright & Co. acted as the placement agent, receiving a fee and warrants as compensation. This move is part of Jaguar’s strategy to strengthen its financial position and support its operational and development goals.
On May 13 and 14, 2025, Jaguar Health, Inc. executed several stock exchange agreements to manage its financial obligations. The company issued common and preferred stock to reduce outstanding royalty interests and replace existing preferred stock, impacting its financial structure and shareholder equity. These transactions are part of Jaguar’s broader strategy to optimize its capital structure and potentially improve its market positioning. Additionally, Jaguar reported a decrease in first-quarter 2025 revenue compared to the previous year and quarter, with a notable increase in sales and marketing expenses due to expanded market access activities.
On May 9, 2025, Jaguar Health released a slide presentation detailing its ongoing efforts to develop and commercialize crofelemer for various indications, including HIV-related diarrhea and short bowel syndrome. Recent studies presented in April 2025 showed promising results for crofelemer in reducing parenteral support in patients with intestinal failure, potentially improving their quality of life. The company is also pursuing additional business development deals and regulatory designations to enhance its market positioning.
On April 30, 2025, Jaguar Health announced promising initial results from a proof-of-concept trial of crofelemer, a novel liquid formulation aimed at reducing the need for total parenteral nutrition (TPN) in patients with microvillus inclusion disease (MVID) and short bowel syndrome with intestinal failure (SBS-IF). The trial demonstrated that crofelemer reduced TPN requirements by up to 27% and 12.5% for MVID and SBS-IF patients, respectively, and showed potential for improving nutrient absorption and quality of life. These findings may support crofelemer’s inclusion in expedited regulatory programs in the EU and US, highlighting its potential as a novel therapeutic option for these rare conditions.
On April 28, 2025, Jaguar Health announced an investor webcast scheduled for April 30, 2025, to discuss preliminary results from a proof-of-concept trial of crofelemer for treating rare diseases like microvillus inclusion disease and short bowel syndrome with intestinal failure. The webcast will cover patient experiences, the drug’s impact on disease progression, and potential regulatory pathways, highlighting Jaguar’s commitment to addressing unmet clinical needs and its strategic positioning in the pharmaceutical industry.
Jaguar Health announced its participation in the 11th Annual Elite Ped-GI Congress 2025 in Abu Dhabi, where they will present proof-of-concept data for their products, including crofelemer. The company is actively pursuing business development opportunities and regulatory designations in the U.S. and Europe, aiming to expand the market reach of crofelemer for various indications, which could significantly impact their market positioning and stakeholder interests.
On March 31, 2025, Jaguar Health closed a private placement, raising approximately $3.448 million through convertible promissory notes and warrants. The funds will be used for working capital and general corporate purposes, with expectations of key catalysts in the second quarter of 2025 related to crofelemer development for rare diseases and cancer therapy-related diarrhea, potentially enhancing the company’s value.
Jaguar Health, Inc. announced a reverse stock split of its common stock at a 1-for-25 ratio, effective March 24, 2025, to comply with Nasdaq listing standards and attract institutional investors. The reverse stock split will reduce the number of shares and increase the share price, with no fractional shares issued; stockholders will receive cash for any fractional shares. The company’s stock will continue trading on Nasdaq under the symbol ‘JAGX’ with a new CUSIP number.